Compile Data Set for Download or QSAR
Report error Found 703 Enz. Inhib. hit(s) with all data for entry = 2622
TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373218(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373342(((2S,3R)-2-(((5-Chloro-3-fluoropyridin-2-yl)amino)...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373137(rac-N-((5-fluoro-1-(2-methyl-5-phenylthiazole-4-ca...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373177(rac-N-(((5S)-1-(biphenylcarbonyl)-5-fluoropiperidi...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373198(rac-N-((1-(5-(4-fluorophenyl)-2-methylthiazole-4-c...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373136(rac-N-((5-fluoro-1-(2-methyl-5-phenylthiazole-4-ca...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373192(rac-N-((5,5-difluoro-1-(5-(3-fluorophenyl)-2-methy...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373153(rac-((2S,3R)-2-(((5-bromopyrimidin-2-yl)amino)meth...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373416(((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyrimidi...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373466((5-Fluoro-2-(pyrimidin-2-yl)phenyl)((2S,3R)-3-meth...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373402((5-Chloro-2-(2H-1,2,3-triazol-2-yl)phenyl)((2S,3R)...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373241(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373429(((2S,3R)-2-(((3-Fluoro-5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373507(((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyrimidi...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373200(rac-3-Fluoro-N-((1-(5-(4-fluorophenyl)-2-methylthi...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373415(((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM50384423(CHEMBL2031485 | US9896452, Example 62)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373342(((2S,3R)-2-(((5-Chloro-3-fluoropyridin-2-yl)amino)...)
Affinity DataIC50: 1nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373257(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373176(rac-N-((1-(biphenylcarbonyl)-5,5-difluoropiperidin...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373356(((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373175(rac-N-((5-fluoro-1-(2-methyl-4-phenylthiazole-5-ca...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373217(rac-((2S,3R)-3-ethyl-2-(((5-ethylpyrimidin-2-yl)am...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373176(rac-N-((1-(biphenylcarbonyl)-5,5-difluoropiperidin...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373352(((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373147(US9896452, Ex. A85 | rac-(5-(4-fluorophenyl)-2-met...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373172(rac-N-((1-(biphenylcarbonyl)-5-hydroxypiperidin-2-...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373465((5-Fluoro-2-(pyrimidin-2-yl)phenyl)((2S,3R)-3-meth...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373240(US9896452, Ex. A1 | US9896452, Example 103 | rac-(...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373277(rac-N-(((1s,4s)-2-(2-methyl-5-phenylthiazole-4-car...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373138(rac-(5-Fluoro-2-((5-(trifluoromethyl)pyridin-2-yla...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373203(rac-N-(((2S,3R)-1-(5-(4-fluorophenyl)-2-methylthia...)
Affinity DataIC50: 2nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373473((2-Fluoro-6-(pyrimidin-2-yl)phenyl)((2S,3R)-3-meth...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373234(US9896452, Ex. A149 | rac-((2S,3R)-3-methyl-2-(((5...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373424(((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373287(((2S,3R)-2-(((5-Chlorobenzo[d]oxazol-2-yl)amino)me...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373177(rac-N-(((5S)-1-(biphenylcarbonyl)-5-fluoropiperidi...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373251(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373501(((2S,3R)-2-(((5-chloropyrimidin-2-yl)amino)methyl)...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373133(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373133(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373289(US9896452, Ex. A84 | ((2S,3R)-2-(((5-Chlorobenzo[d...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373370(((2S,3R)-2-(((5-Fluorobenzo[d]oxazol-2-yl)amino)me...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM50384428(CHEMBL2031491 | US9896452, Example 8)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM50384427(CHEMBL2031490 | US9896452, Example 139)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373257(rac-((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyri...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373499(((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyrimidi...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373383(((2S,3R)-2-(((5-Fluorobenzo[d]oxazol-2-yl)amino)me...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373349(((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Eolas Therapeutics

US Patent
LigandPNGBDBM373289(US9896452, Ex. A84 | ((2S,3R)-2-(((5-Chlorobenzo[d...)
Affinity DataIC50: 3nMAssay Description:Measurement of [Ca2+]i using a FLIPR: CHO-OX1 or CHO-OX2 cells are seeded into black-walled clear-base 384-well plates (Costar) at a density of 20,00...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
US Patent

Displayed 1 to 50 (of 703 total ) | Next | Last >>
Jump to: